Pieris Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/812,069 Titled "Muteins Of Human Lipocalin 2 With Affinity For A Given Target (For The Diagnosis And Treatment Of Tumor Diseases)"
Pieris Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/812,069 Titled "Muteins Of Human Lipocalin 2 With Affinity For A Given Target (For The Diagnosis And Treatment Of Tumor Diseases)"
Pieris Pharmicals已收到允許其美國專利申請的通知 16/812,069，標題爲 “對給定靶點具有親和力（用於腫瘤疾病的診斷和治療）的人類Lipocalin 2的突變蛋白”
Pieris Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/812,069 Titled "Muteins Of Human Lipocalin 2 With Affinity For A Given Target (For The Diagnosis And Treatment Of Tumor Diseases)"
Pieris Pharmicals已收到允許其美國專利申請的通知 16/812,069，標題爲 “對給定靶點具有親和力（用於腫瘤疾病的診斷和治療）的人類Lipocalin 2的突變蛋白”
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。